Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older, regardless of gender.
- You are willing and able to follow the study schedule and requirements.
- You have been formally diagnosed with multiple myeloma according to established diagnostic guidelines, and your disease can be measured through specific blood or urine tests showing certain protein levels above defined thresholds (confirm with trial site).
- You have already received at least 3 previous rounds of treatment, which must have included three specific types of therapy: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment (confirm with trial site for exact drug names).
Who may not be able to join:
- You have a known allergy or sensitivity to any ingredient in the treatment being studied.
- You have been diagnosed with an active form of blood cancer called plasma cell leukemia, or a condition called systemic light chain amyloidosis (confirm with trial site).
- You have an active serious mental health condition, serious physical health condition, or other symptoms that could affect your treatment or your ability to give informed consent, as judged by the study doctor.
- Your disease has already been treated with two specific drugs — pomalidomide and selinexor — and did not respond to them (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 008613502181109
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.